Datasets:
Inabia-AI
/
continued-pretraining-jsonl

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
5.46k
4.2. Grants to Cugene................................................................................................... 36
4.3. Sublicenses............................................................................................................ 36
4.4. No Implied Licenses ............................................................................................. 37
4.5. Confirmatory Patent License ................................................................................ 37
4.6. Exclusivity ............................................................................................................ 37
ARTICLE 5 DEVELOPMENT AND COMMERCIALIZATION BY ABBVIE........................ 38
5.1. In General.............................................................................................................. 38
5.2. Diligence ............................................................................................................... 38
5.3. Manufacturing Technology Transfer .................................................................... 38
5.4. Subcontracting; Distributors ................................................................................. 40
5.5. Records; Development and Commercialization Reports...................................... 41
5.6. Regulatory Activities ............................................................................................ 42
5.7. Adverse Event and Safety Information Agreement .............................................. 42
ARTICLE 6 COLLABORATION MANAGEMENT.................................................................. 42
6.1. Joint Governance Committee................................................................................ 42
6.2. General Provisions Applicable to the JGC ........................................................... 44
6.3. Working Groups.................................................................................................... 46
6.4. Alliance Managers. ............................................................................................... 46
ARTICLE 7 PAYMENTS AND RECORDS............................................................................... 47
7.1. Upfront Payment................................................................................................... 47
7.2. License Option Exercise Payment ........................................................................ 47
7.3. Development Milestone Events ............................................................................ 47
7.4. Sales Milestone Events ......................................................................................... 49
7.5. Royalties ............................................................................................................... 49
7.6. Estimated Sales Levels ......................................................................................... 52
7.7. Royalty Payments and Reports ............................................................................. 52
7.8. Mode of Payment.................................................................................................. 52
7.9. Taxes. .................................................................................................................... 52
7.10. Interest on Late Payments..................................................................................... 54
7.11. Financial Records.................................................................................................. 54
7.12. Audit ..................................................................................................................... 54
7.13. Right to Offset....................................................................................................... 55
7.14. Diagnostic and Veterinary Products ..................................................................... 55
7.15. No Other Compensation ....................................................................................... 55
7.16. No Limitation........................................................................................................ 55
7.17. Financial Obligations Under WuXi Agreements.................................................. 55
ARTICLE 8 INTELLECTUAL PROPERTY .............................................................................. 55
8.1. Ownership of Intellectual Property....................................................................... 55
8.2. Prosecution and Maintenance of Patents .............................................................. 57
8.3. Enforcement of Patents ......................................................................................... 62
8.4. Infringement Claims by Third Parties................................................................... 67
8.5. Invalidity or Unenforceability Defenses or Actions ............................................. 68
8.6. Third Party Licenses and Patents.......................................................................... 71
8.7. Product Trademarks .............................................................................................. 72
8.8. Inventor's Remuneration ...................................................................................... 73
ARTICLE 9 CONFIDENTIALITY AND NON-DISCLOSURE ................................................ 74
9.1. Confidentiality Obligations................................................................................... 74
9.2. Permitted Disclosures ........................................................................................... 75
9.3. Additional Permitted Disclosures and Use by AbbVie......................................... 76
9.4. Additional Permitted Disclosures and Use by Cugene ......................................... 76
9.5. Use of Name ......................................................................................................... 77
9.6. Public Announcements ......................................................................................... 77
9.7. Publications........................................................................................................... 78
9.8. Return of Confidential Information ...................................................................... 79
ARTICLE 10 REPRESENTATIONS AND WARRANTIES...................................................... 79
10.1. Mutual Representations and Warranties ............................................................... 79
10.2. Additional Representations, Warranties and Covenants of Cugene ..................... 79
10.3. Additional Covenants of Cugene .......................................................................... 85
10.4. Additional Representations, Warranties and Covenants of AbbVie..................... 87
10.5. DISCLAIMER OF WARRANTIES..................................................................... 88
10.6. Anti-Bribery and Anti-Corruption Compliance.................................................... 88
ARTICLE 11 INDEMNITY......................................................................................................... 88
11.1. Indemnification of Cugene ................................................................................... 88
11.2. Indemnification of AbbVie ................................................................................... 89
11.3. Indemnification Procedures .................................................................................. 89
11.4. Special, Indirect and Other Losses........................................................................ 92
11.5. Insurance ............................................................................................................... 92
ARTICLE 12 TERM AND TERMINATION .............................................................................. 93
12.1. Term and Expiration ............................................................................................. 93
12.2. Termination........................................................................................................... 93
12.3. Rights in Bankruptcy ............................................................................................ 95
12.4. Consequences of Termination............................................................................... 96
12.5. Transition Agreement. .......................................................................................... 99
12.6. Reverse Royalty .................................................................................................. 102
12.7. AbbVie Rights in Lieu of Termination............................................................... 102
12.8. Remedies............................................................................................................. 103
12.9. Accrued Rights; Surviving Obligations .............................................................. 103
ARTICLE 13 MISCELLANEOUS ............................................................................................ 104
13.1. Force Majeure ..................................................................................................... 104
13.2. Export Control .................................................................................................... 104
13.3. Assignment ......................................................................................................... 104
13.4. Severability ......................................................................................................... 106
13.5. Dispute Resolution.............................................................................................. 106
13.6. Governing Law ................................................................................................... 107
13.7. Notices ................................................................................................................ 107
13.8. Entire Agreement; Amendments......................................................................... 108
13.9. English Language................................................................................................ 108
13.10. Equitable Relief .................................................................................................. 108
13.11. Waiver and Non-Exclusion of Remedies............................................................ 109
13.12. No Benefit to Third Parties ................................................................................. 109
13.13. Further Assurance ............................................................................................... 109
13.14. Relationship of the Parties .................................................................................. 109
13.15. References........................................................................................................... 110
13.16. Construction........................................................................................................ 110
13.17. Performance by Affiliates ................................................................................... 110
13.18. Change in Control of Cugene ............................................................................. 110
13.19. Counterparts........................................................................................................ 111
Schedules
Schedule 1.54 Corporate Names
Schedule 1.94 Existing Patents Schedule